Diclofenac-13C6 (sodium)

Diclofenac-13C6 (sodium)

• CAS Number: 1261393-73-0
• UNSPSC Description: Diclofenac-13C6 (Sodium) is the 13C6 labeled Diclofenac (Sodium). Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade.
• Target Antigen: Apoptosis; COX; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Apoptosis;Immunology/Inflammation;Others
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/diclofenac-13c6-sodium.html
• Solubility: 10 mM in DMSO
• Smiles: O=C(O[Na])C[13C]([13CH]=[13CH][13CH]=[13CH]1)=[13C]1NC2=C(C=CC=C2Cl)Cl
• Molecular Weight: 324.09
• References & Citations: [1]Chiho Kudo, et al. Diclofenac Inhibits Proliferation and Differentiation of Neural Stem Cells. Biochem Pharmacol. 2003 Jul 15;66(2):289-95.|[2]Labib MB, et al. Design, synthesis of novel isoindoline hybrids as COX-2 inhibitors: Anti-inflammatory, analgesic activities and docking study. Bioorg Chem. 2018 Oct;80:70-80.|[3]Riendeau D, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported